Distinguished in Dysarthria

Dr. James D. Berry

Neurology
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Distinguished in Dysarthria
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Berry is a Neurologist in Boston, Massachusetts. Dr. Berry is rated as a Distinguished provider by MediFind in the treatment of Dysarthria. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Spinal and Bulbar Muscular Atrophy, and Gastrostomy. Dr. Berry is currently accepting new patients.

His clinical research consists of co-authoring 182 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Dysarthria.

Specialties
Neurology
Licenses
Psychiatry & Neurology in MA
Hospital Affiliations
Massachusetts General Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Evaluation of the Safety, Tolerability, Efficacy, and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis: Open-Label Extension
Evaluation of the Safety, Tolerability, Efficacy, and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis: Open-Label Extension
Enrollment Status: Completed
Publish Date: August 13, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
Enrollment Status: Completed
Publish Date: September 24, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Phase: Phase 2
Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: No_longer_available
Publish Date: April 23, 2024
Intervention Type: Biological
A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS
A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS
Enrollment Status: Completed
Publish Date: February 29, 2024
Intervention Type: Other, Biological
Study Phase: Phase 3
Phase 2a Study of the Expansion and Infusion of Autologous T-Regulatory Cells in Amyotrophic Lateral Sclerosis
Phase 2a Study of the Expansion and Infusion of Autologous T-Regulatory Cells in Amyotrophic Lateral Sclerosis
Enrollment Status: Unknown
Publish Date: October 06, 2021
Intervention Type: Biological, Other
Study Drug: Autologous Treg Cell Infusion
Study Phase: Phase 2
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Enrollment Status: Completed
Publish Date: January 13, 2020
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
Enrollment Status: Completed
Publish Date: May 07, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Study for the Discovery and Validation of ALS Biomarkers
A Multicenter Study for the Discovery and Validation of ALS Biomarkers
Enrollment Status: Completed
Publish Date: May 30, 2017
View 8 Less Clinical Trials

180 Total Publications

What can vowel acoustics reveal about the communicative participation of people living with ALS?
What can vowel acoustics reveal about the communicative participation of people living with ALS?
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: December 15, 2025
Similar Doctors
Distinguished in Dysarthria
Dr. Leigh R. Hochberg
Neurology
Distinguished in Dysarthria
Dr. Leigh R. Hochberg
Neurology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Leigh Hochberg is a Neurologist in Boston, Massachusetts. Dr. Hochberg is rated as a Distinguished provider by MediFind in the treatment of Dysarthria. His top areas of expertise are Dysarthria, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Stroke, and Deep Brain Stimulation. Dr. Hochberg is currently accepting new patients.

Advanced in Dysarthria
Dr. Sydney S. Cash
Neurology
Advanced in Dysarthria
Dr. Sydney S. Cash
Neurology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sydney Cash is a Neurologist in Boston, Massachusetts. Dr. Cash is rated as a Distinguished provider by MediFind in the treatment of Dysarthria. His top areas of expertise are Seizures, Epilepsy, Generalized Tonic-Clonic Seizure, Absence Seizure, and Deep Brain Stimulation. Dr. Cash is currently accepting new patients.

Advanced in Dysarthria
Dr. Jeremy D. Schmahmann
Neurology
Advanced in Dysarthria
Dr. Jeremy D. Schmahmann
Neurology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Schmahmann is a Neurologist in Boston, Massachusetts. Dr. Schmahmann is rated as an Elite provider by MediFind in the treatment of Dysarthria. His top areas of expertise are Spinocerebellar Ataxia, Acute Cerebellar Ataxia, Olivopontocerebellar Atrophy, Drug Induced Dyskinesia, and Gastrostomy. Dr. Schmahmann is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Berry's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile